

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Brain cancer	Epidermal growth factor receptor (EGFR); isocitrate dehydrogenase 1 (IDH1); platelet derived growth factor receptor- $\alpha$ (PDGFRA); neurofibromin 1 (NF1)	<p>Genomic studies identified a classification system for glioblastoma subtypes that could help guide treatment decisions. Based on expression analysis of 200 samples from glioblastoma patients, gliomas were classified into 4 subtypes—classical, neuronal, proneural and mesenchymal. Alterations in <i>EGFR</i>, <i>NF1</i> or <i>PDGFRA/IDH1</i> expression were characteristic of the classical, mesenchymal or proneural subtypes, respectively. Next steps could include using the findings to identify therapeutics for the specific subtypes.</p> <p>GlobeImmune Inc.'s GI-3000, an EGFR inhibitor, is in preclinical testing to treat brain cancer. At least five other companies have EGFR inhibitors in development to treat cancer.</p> <p><b>SciBX 3(5); doi:10.1038/scibx.2010.141</b>  <b>Published online Feb. 4, 2010</b></p>	Findings unpatented; licensing status not applicable	<p>Verhaak, R. <i>et al. Cancer Cell</i>; published online Jan. 19, 2010; doi:10.1016/j.ccr.2009.12.020</p> <p><b>Contact:</b> D. Neil Hayes, The University of North Carolina at Chapel Hill, Chapel Hill, N.C.            e-mail: <a href="mailto:hayes@med.unc.edu">hayes@med.unc.edu</a></p>